pharma · Cholestatic liver disease · Cystic Fibrosis · PRQR
ProQR Therapeutics N.V
ProQR Therapeutics N.V.
ProQR Therapeutics is a pharma organization headquartered in Leiden, NL. It trades on NYSE under ticker PRQR. Primary therapeutic focus areas include Cholestatic liver disease, Cystic Fibrosis, Autosomal Dominant Retinit
Leiden, NL HQ
2012 Founded
204 Employees
Public company Type
PRQR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Leiden, NL
- Founded
- 2012
- Employees
- 204
- Programs
- 6
- Drugs
- 2
- Patents
- 19
QR-1123
Phase 2 · small molecule · Autosomal Dominant Retinitis Pigmentosa
QR-1123 for Autosomal Dominant Retinitis Pigmentosa is a Phase 2 program (small_molecule) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).
Internal code PQ-1123-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ProQR Therapeutics N.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Autosomal Dominant Retinitis Pigmentosa
- Status
- active
- Trials
- 1